14 completed. 14 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 14 |
| Phase 1 | 2 | Completed 2 |
Follow Tremor: new trials by email Literature Review of Tremor trials Research Report on Tremor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease Placebo, Suvecaltamide - Parkinson Disease, Tremor | Phase 2 | Completed | Jazz Pharmaceuticals | 169 | 2022-12-01 | 2026-01-15 |
| A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET) JZP385, Placebo - Essential Tremor | Phase 2 | Completed | Jazz Pharmaceuticals | 420 | 2021-12-06 | 2025-07-24 |
| A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease Cannabidiol, Placebo - Parkinson Disease | Phase 2 | Completed | University of Colorado, Denver | 74 | 2018-09-05 | 2024-07-23 |
| Effectiveness of Botox on Reducing Rest Tremor in Parkinson's Disease Onabotulinumtoxin A Injection, Placebo - Parkinson Disease | Phase 2 | Completed | University of North Carolina, Chapel Hill | 16 | 2018-03-22 | 2020-08-17 |
| A Study to Evaluate SAGE-217 in Participants With Essential Tremor SAGE-217, Placebo - Essential Tremor | Phase 2 | Completed | Biogen | 34 | 2017-03-24 | 2023-11-28 |
| A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease cannabidiol - Parkinson's Disease | Phase 2 | Completed | University of Colorado, Denver | 13 | 2016-10-01 | 2019-02-19 |
| Effects of Octanoic Acid for Treatment of Essential Voice Tremor Octanoic acid, Inactive capsule - Essential Voice Tremor, Vocal Tremor | Phase 1 / Phase 2 | Completed | Syracuse University | 17 | 2013-07-01 | 2018-08-20 |
| Randomised Crossover Trial of DBS of Differential PSA Regions in Parkinson's Disease and Tremor Up to 3 mA, 60 us, 130 Hz deep brain stimulation, Empirical unblinded deep brain stimulation programming - Parkinson's Disease, Tremor | Phase 2 | Completed | The University of Western Australia | 39 | 2012-08-01 | 2021-05-18 |
| Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Tremor: A Customized Approach incobotulinumtoxinA, Saline - Parkinson, Tremor | Phase 2 | Completed | Yale University | 33 | 2012-08-01 | 2016-03-14 |
| Voice Tremor in Spasmodic Dysphonia: Central Mechanisms and Treatment Response Sodium oxybate - Spasmodic Dysphonia, Voice Tremor | Phase 2 | Completed | Kristina Simonyan | 53 | 2012-07-01 | 2017-11-22 |
| A Pilot Efficacy and Safety Study of ST101 in Essential Tremor ST101, Placebo - Essential Tremor | Phase 2 | Completed | Sonexa Therapeutics, Inc. | 25 | 2011-04-01 | 2012-01-06 |
| A Proof of Concept Study of the Effectiveness of Carisbamate in the Treatment of Essential Tremor Carisbamate, Placebo - Essential Tremor, Movement Disorders | Phase 2 | Completed | SK Life Science, Inc. | 62 | 2007-08-01 | 2013-01-24 |
| Efficacy of Levetiracetam in Essential Tremor levetiracetam, placebo - Essential Tremor | Phase 1 / Phase 2 | Completed | Southern California Institute for Research and Education | 10 | 2005-01-01 | 2009-04-17 |
| Effect of Alcohol on Tremors Alcohol - Tremor | Phase 2 | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | 23 | 1999-01-01 | 2008-03-04 |
Essential Tremor (7) · Parkinson Disease (5) · Movement Disorders (3) · Anxiety Disorders (2) · Dyskinesias (2) · Dysphonia (2) · Marijuana Abuse (2) · Psychotic Disorders (2) · Dermatitis, Seborrheic (1) · Dystonia (1) · Voice Disorders (1)
Nervous System Diseases (14) · Neurologic Manifestations (14) · Pathological Conditions, Signs and Symptoms (14) · Signs and Symptoms (14) · Dyskinesias (12) · Central Nervous System Diseases (11) · Movement Disorders (8) · Basal Ganglia Diseases (5) · Brain Diseases (5) · Neurodegenerative Diseases (5) · Parkinsonian Disorders (5) · Synucleinopathies (5) · Chemically-Induced Disorders (2) · Laryngeal Diseases (2) · Mental Disorders (2)
Cannabidiol (2) · Botulinum Toxins, Type A (1) · Ethanol (1) · Levetiracetam (1) · S-2-O-carbamoyl-1-o-chlorophenyl-ethanol (1) · Saline Solution (1) · Sodium Chloride (1) · Sodium Oxybate (1) · incobotulinumtoxinA (1) · octanoic acid (1) · zuranolone (1)
Jazz Pharmaceuticals (2) · University of Colorado, Denver (2) · Biogen (1) · Kristina Simonyan (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · SK Life Science, Inc. (1) · Sonexa Therapeutics, Inc. (1) · Southern California Institute for Research and Education (1) · Syracuse University (1) · The University of Western Australia (1) · University of North Carolina, Chapel Hill (1) · Yale University (1)
United States (12) · Germany (2) · Poland (2) · Spain (2) · Australia (1)
Bahman Jabbari, MD (1) · Christopher Lind, MBChB, FRACS (1) · Daniel A Roque, MD (1) · Kristina Simonyan, MD, PhD (1) · Maureen A Leehey, M.D. (1) · Maureen Leehey (1) · Soren Y Lowell, PhD (1) · Steven S Schreiber, MD (1)
PMID 14718713, PMID 15210907, PMID 20201005, PMID 21594724, PMID 22454323, PMID 23408867, PMID 25929664, PMID 27808415, PMID 28789780, PMID 30382161, PMID 37448353, PMID 38466972
R01DC012545 (1), R03DC012429 (1)